New

Capstan Therapeutics

The AI engine Fit Assessment

Beta

Capstan Therapeutics develops RNA-based therapies using targeted delivery systems to enhance treatments for oncology, fibrosis, and inflammation-related diseases.

Blurb

Capstan Therapeutics develops in vivo mRNA and gene-editing medicines for a broad range of diseases.

HQ Location

San Diego (United States)

Founded

2021

Employees

51 - 200

Total funding raised

$2.44B

Last Funding Event

Acquired by AbbVie, June 2025

Smart insights

  • 1Y headcount growth: 19%
  • Headcount-to-last-round ratio: 1.1 employees/$M

Capstan Therapeutics develops in vivo mRNA and gene-editing medicines for a broad range of diseases using its proprietary CellSeeker tLNP platform. Its technology deploys targeted lipid nanoparticles conjugated with protein binders—such as antibodies—to reprogram specific cell types within the body, including CAR-T cells, without ex vivo manipulation. The lead candidate, CPTX2309, delivers an anti-CD19 CAR payload to CD8⁺ T cells and aims to reset B cell–driven autoimmune disease, currently in Phase 1 trials.